Aurobindo Pharma has announced the completion of a routine inspection by the US Food and Drug Administration (FDA) at Lannett Company LLC, its wholly owned step-down subsidiary, in Seymour, Indiana, US.

The FDA conducted the inspection from August 17 to August 21, 2026, as part of its routine regulatory oversight of the facility.

According to Aurobindo Pharma, the inspection concluded with 4 observations, which the company described as procedural in nature. The company said it will submit its response to the FDA within the stipulated timeline.

Aurobindo Pharma said it remains committed to maintaining robust quality and compliance standards across its manufacturing facilities. The company will keep the stock exchanges informed of any further developments related to the inspection, as required under applicable regulations.

The disclosure was made by Aurobindo Pharma on August 24, 2026, pursuant to Regulation 30 of the Securities and Exchange Board of India (SEBI) Listing Obligations and Disclosure Requirements Regulations, 2015.